Benzinga | Feb 2, 2021 07:09AM EST

Recap: Haemonetics Q3 Earnings



Shares of Haemonetics (NYSE:HAE) were flat in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 13.83% year over year to $0.81, which beat the estimate of $0.65.

Revenue of $240,371,000 declined by 7.18% from the same period last year, which beat the estimate of $224,290,000.

Looking Ahead

Haemonetics hasn't issued any earnings guidance for the time being.

Haemonetics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Feb 02, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/6nszefg7

Price Action

Company's 52-week high was at $129.92

Company's 52-week low was at $63.41

Price action over last quarter: Up 16.87%

Company Profile

Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.